Evidence map›Paper›PMID 41381836›Full record

ArticleScientific reports2025

Hyaluronic acid capped cubosomes co-loaded with antitumor agents towards the treatment of colorectal cancer.

Muhammad Khalil Ur Rehman, Sibgha Batool, Sanghyun Woo, Ali H Alamri, Adel Al Fatease, Zahrah Ali Asiri, Nabil K Alruwaili, Mujeeb Ur Rehman, Fakhar Ud Din

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Muhammad Khalil Ur RehmanDepartment of Pharmacy , Quaid-i-Azam University , Islamabad, Pakistan.
Sibgha BatoolDepartment of Pharmacy , Quaid-i-Azam University , Islamabad, Pakistan.
Sanghyun WooCollege of Pharmacy , Hanyang University , 55 Hanyangdaehak-ro, Sangnok-gu, Ansan, 15588, South Korea.
Ali H AlamriDepartment of Pharmaceutics College of Pharmacy , King Khalid University , Abha, 62529, Saudi Arabia.
Adel Al FateaseDepartment of Pharmaceutics College of Pharmacy , King Khalid University , Abha, 62529, Saudi Arabia.
Zahrah Ali AsiriDepartment of Pharmaceutics College of Pharmacy , King Khalid University , Abha, 62529, Saudi Arabia.
Nabil K AlruwailiPharmaceutics Department College of Pharmacy , Jouf university , Sakaka, Saudi Arabia.
Mujeeb Ur RehmanInternational Center for Chemical and Biological Sciences, L.E.J. Nanotechnology Center, H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, 75270, Pakistan.
Fakhar Ud DinDepartment of Pharmacy , Quaid-i-Azam University , Islamabad, Pakistan. fudin@qau.edu.pk.

Funding

Higher Education Commision, Pakistan 20-14604/NRPU/R&D/HEC/2021
6 · The paper itself

Abstract

Colorectal cancer (CRC) is the 3rd most lethal type of cancer-linked deaths worldwide. Combination chemotherapy offers a better therapeutic response against CRC than single drug therapy. The purpose of this study was to successfully encapsulate Capecitabine (CAP) and Regorafenib (REG) in liquid crystal nanoparticles or cubosomes (CUBs) matrix for targeting CRC following intravenous (IV) administration. Active targeting of the CUBs was achieved by surface capped hyaluronic acid (HA) owing to its binding affinity with complex differentiation (CD-44) receptors on cancer stem cells. The HA-capped REG-CAP co-loaded CUBs (HA-REG-CAP-CUBs) were prepared via the Top-bottom method and optimized using Design Expert

Indexed as

Antineoplastic AgentsCapecitabineColorectal NeoplasmsHyaluronic AcidNanoparticlesPyridinesAnimalsCell Line, TumorDrug CarriersDrug LiberationHumansMaleMiceParticle SizePhenylurea CompoundsRatsAntineoplastic AgentsCapecitabineDrug CarriersHyaluronic AcidPhenylurea CompoundsPyridinesregorafenibCapecitabineColorectal cancerHyaluronic acidRegorafenib

Identifiers

PMID41381836
PMCPMC12816657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.